4 February 2026
SSE plcQ3 Trading Statement 4 February 2026 This Trading Statement updates on strategic progress and operational performance for the nine-month period ending 31 December…
GSK delivers strong 2025 performance and re-affirms long-term outlooks Sales, profit and earnings growth driven by strong Specialty Medicines performance 2025 Q4 2025 £m…
3 February 2026
PepsiCo Reports Fourth Quarter and Full-Year 2025 Results; Affirms 2026 Financial Outlook; Announces Annual Dividend Increase Reported (GAAP) Fourth Quarter and Full-Year 2025 Results…
2 February 2026
3i Infrastructure plc – Q3 Performance update 3i Infrastructure plc (‘3iN’ or the ‘Company’) is an investment company whose purpose is to invest responsibly…
INTERIM RESULTS ANNOUNCEMENT Results for the twelve months ended 31 December 2025 Performance Highlights Net Asset Value At 31 December 2025 At 31 December…
Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers Recommendation based on MATTERHORN Phase III trial…
AstraZeneca begins trading on the New York Stock Exchange Ordinary shares now trade across the NYSE, LSE and STO under a harmonised global listing structure…
30 January 2026
Income Statement Summary In billions, except percentages and per share data. Q1 2026 % change is calculated over the comparable prior-year period. USD…